Abstract
Introduction: Patients requiring major cardiovascular surgery are likely to be prescribed antiplatelet agents either alone or in combination. By virtue of antiplatelet agent effect, they can potentially increase bleeding complications, especially if used in combination. This article aims to review the evidence and make appropriate recommendations regarding these agents. Aspirin: 16 papers are reviewed which concern surgery whilst taking aspirin. The bulk of the evidence is from the coronary bypass setting. Clopidogrel: 14 papers are reviewed which concern surgery whilst taking clopidogrel. Dipyridamole: 2 papers are reviewed concerning dipyridamole. Cilostazol: No trials are available concerning surgery and cilostazol. Several relevant publications are reviewed. Conclusion: It is the recommendation of the authors that aspirin should usually be continued perioperatively, whilst clopidogrel should be stopped for seven days prior to surgery if at all possible.
Keywords: Aspirin, platelet aggregation inhibitors, cardiac surgical procedures, vascular surgical procedures, haemorrhage, post-operative complications
Current Drug Safety
Title: Oral Antiplatelet Agents and Bleeding Risk in Relation to Major Cardiovascular Surgery
Volume: 1 Issue: 3
Author(s): James McCaslin, Jonathan Smout, Patrick Kesteven and Gerard Stansby
Affiliation:
Keywords: Aspirin, platelet aggregation inhibitors, cardiac surgical procedures, vascular surgical procedures, haemorrhage, post-operative complications
Abstract: Introduction: Patients requiring major cardiovascular surgery are likely to be prescribed antiplatelet agents either alone or in combination. By virtue of antiplatelet agent effect, they can potentially increase bleeding complications, especially if used in combination. This article aims to review the evidence and make appropriate recommendations regarding these agents. Aspirin: 16 papers are reviewed which concern surgery whilst taking aspirin. The bulk of the evidence is from the coronary bypass setting. Clopidogrel: 14 papers are reviewed which concern surgery whilst taking clopidogrel. Dipyridamole: 2 papers are reviewed concerning dipyridamole. Cilostazol: No trials are available concerning surgery and cilostazol. Several relevant publications are reviewed. Conclusion: It is the recommendation of the authors that aspirin should usually be continued perioperatively, whilst clopidogrel should be stopped for seven days prior to surgery if at all possible.
Export Options
About this article
Cite this article as:
McCaslin James, Smout Jonathan, Kesteven Patrick and Stansby Gerard, Oral Antiplatelet Agents and Bleeding Risk in Relation to Major Cardiovascular Surgery, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934486
DOI https://dx.doi.org/10.2174/157488606777934486 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Action of Hypertonic Saline Resuscitation in Severe Sepsis and Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabolic Acidosis in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Endothelin System in Cardiovascular Disease and the Potential Therapeutic Perspectives of its Inhibition
Current Topics in Medicinal Chemistry Structure-Function Relationships of Iodinated Contrast Media and Risk of Nephrotoxicity
Current Medicinal Chemistry Cardiovascular Effects of Ghrelin and Growth Hormone Secretagogues
Cardiovascular & Hematological Disorders-Drug Targets The Crosstalk between Gut Inflammation and Gastrointestinal Disorders During Acute Pancreatitis
Current Pharmaceutical Design Enhancement of Dissolution Rate of Furosemide Using a Solid Dispersion with D-Glucosamine HCl
Current Pharmaceutical Analysis Early Vascular Aging: A New Target for Hypertension Treatment
Current Pharmaceutical Design Obesity, Metabolic Syndrome, Diabetes and Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology
Current Pharmaceutical Design An Overview of Data Mining Algorithms in Drug Induced Toxicity Prediction
Mini-Reviews in Medicinal Chemistry RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews Role of Adiponectin in the Metabolic Syndrome: Current Perspectives on its Modulation as a Treatment Strategy
Current Pharmaceutical Design Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews Parathyroid Hypertension: A Rare, but Curable form of Secondary Hypertension
Current Hypertension Reviews Matrix Metalloproteinases as Drug Targets in Preeclampsia
Current Drug Targets The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research